These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 23588769)

  • 1. ACP Journal Club: metformin reduced CV events compared with glipizide in patients with type 2 diabetes and CAD.
    Tanner M
    Ann Intern Med; 2013 Apr; 158(8):JC4. PubMed ID: 23588769
    [No Abstract]   [Full Text] [Related]  

  • 2. ACP Journal Club. Rosiglitazone was noninferior to metformin plus sulfonylurea for CV events but increased risk for HF and fractures in type 2 diabetes.
    Lipscombe LL
    Ann Intern Med; 2009 Oct; 151(8):JC4-8. PubMed ID: 19841445
    [No Abstract]   [Full Text] [Related]  

  • 3. ACP Journal Club. Adding prompt revascularization to medical therapy did not reduce mortality or CV events in patients with type 2 diabetes and CAD.
    Poirier P
    Ann Intern Med; 2009 Oct; 151(8):JC4-5. PubMed ID: 19841443
    [No Abstract]   [Full Text] [Related]  

  • 4. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis.
    Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
    Diabetes Obes Metab; 2012 Sep; 14(9):803-9. PubMed ID: 22486923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ACP Journal Club. Review: Metformin reduces risk for CV mortality compared with other oral diabetes drugs or placebo in type 2 diabetes.
    Lipscombe L
    Ann Intern Med; 2009 Apr; 150(8):JC4-8. PubMed ID: 19391221
    [No Abstract]   [Full Text] [Related]  

  • 6. ACP Journal Club. Valsartan reduced diabetes but not CV events in patients with impaired glucose tolerance and CV risk factors.
    Ann Intern Med; 2010 Jun; 152(12):JC6-9. PubMed ID: 20547903
    [No Abstract]   [Full Text] [Related]  

  • 7. ACP Journal Club. Review: Intensive glucose control reduced some CV events but did not change mortality in type 2 diabetes.
    Lipscombe LL
    Ann Intern Med; 2009 Sep; 151(6):JC3-6. PubMed ID: 19755352
    [No Abstract]   [Full Text] [Related]  

  • 8. ACP journal club. Intensive glucose control increased mortality and did not prevent CV events compared with standard glucose control in type 2 diabetes.
    Grubina R; Smith SA
    Ann Intern Med; 2011 May; 154(10):JC5-02. PubMed ID: 21576520
    [No Abstract]   [Full Text] [Related]  

  • 9. A short-term cost-of-treatment model for type 2 diabetes: comparison of glipizide gastrointestinal therapeutic system, metformin, and acarbose.
    Ramsdell JW; Grossman JA; Stephens JM; Botteman MF; Arocho R
    Am J Manag Care; 1999 Aug; 5(8):1007-24. PubMed ID: 10558125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Probable hypoglycemic adverse drug reaction associated with prickly pear cactus, glipizide, and metformin in a patient with type 2 diabetes mellitus.
    Sobieraj DM; Freyer CW
    Ann Pharmacother; 2010; 44(7-8):1334-7. PubMed ID: 20516361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ACP Journal Club. Nateglinide did not reduce diabetes or CV events in patients with impaired glucose tolerance and CV risk factors.
    Farkouh M
    Ann Intern Med; 2010 Jun; 152(12):JC6-10. PubMed ID: 20547892
    [No Abstract]   [Full Text] [Related]  

  • 12. ACP Journal Club. Screening for CAD in asymptomatic patients with type 2 diabetes did not reduce risk for cardiac events.
    Farkouh ME
    Ann Intern Med; 2009 Aug; 151(4):JC2-7. PubMed ID: 19687481
    [No Abstract]   [Full Text] [Related]  

  • 13. ACP Journal Club. Benazepril plus amlodipine reduced CV events more than benazepril plus hydrochlorothiazide in hypertension with or without diabetes.
    Merugu S
    Ann Intern Med; 2010 Oct; 153(8):JC4-2. PubMed ID: 20956698
    [No Abstract]   [Full Text] [Related]  

  • 14. One year comparative trial of metformin and glipizide in type 2 diabetes mellitus.
    Campbell IW; Menzies DG; Chalmers J; McBain AM; Brown IR
    Diabete Metab; 1994; 20(4):394-400. PubMed ID: 7843470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ACP Journal Club. Intensive and standard glucose control did not differ for major CV events or death in poorly controlled type 2 diabetes.
    Booth GL
    Ann Intern Med; 2009 Mar; 150(6):JC3-8. PubMed ID: 19306490
    [No Abstract]   [Full Text] [Related]  

  • 16. ACP Journal Club. Review: DPP-4 inhibitors are less effective than metformin for reducing HbA(1c) in type 2 diabetes.
    Chatterjee S
    Ann Intern Med; 2012 Jul; 157(2):JC2-13. PubMed ID: 22801704
    [No Abstract]   [Full Text] [Related]  

  • 17. Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study.
    Sadikot SM; Mogensen CE
    Diabetes Res Clin Pract; 2008 Dec; 82(3):391-5. PubMed ID: 18945509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ACP Journal Club. Adding omeprazole to clopidogrel reduced GI events and did not increase CV events.
    Chow CK
    Ann Intern Med; 2011 Mar; 154(6):JC3-7. PubMed ID: 21403070
    [No Abstract]   [Full Text] [Related]  

  • 19. ACP Journal Club. Use of ≥ 1 antihypertensive drug at bedtime reduced CV events more than use of all drugs in the morning in CKD.
    Sinha AD; Agarwal R
    Ann Intern Med; 2012 Jun; 156(12):JC6-8. PubMed ID: 22711109
    [No Abstract]   [Full Text] [Related]  

  • 20. ACP Journal Club. Aspirin and/or antioxidants did not prevent CV events in diabetes and peripheral arterial disease.
    Farkouh ME
    Ann Intern Med; 2009 Jan; 150(2):JC1-8. PubMed ID: 19172713
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.